var data={"title":"Mexiletine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Mexiletine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6577?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=mexiletine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Mexiletine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=mexiletine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Mexiletine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709085\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Mortality:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">In the National Heart, Lung, and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multicenter, randomized, double-blind study in patients with asymptomatic non&ndash;life-threatening ventricular arrhythmias who had an myocardial infarction (MI) more than 6 days but less than 2 years previously, an excessive mortality or nonfatal cardiac arrest rate (7.7%) was seen in patients treated with encainide or flecainide compared with that seen in patients assigned to carefully matched placebo-treated groups (3%). The average duration of treatment with encainide or flecainide in this study was 10 months.</p>\n        <p style=\"text-indent:0em;\">The applicability of the CAST results to other populations (eg, those without recent MI) is uncertain. Considering the known proarrhythmic properties of mexiletine and the lack of evidence of improved survival for any antiarrhythmic drug in patients without life-threatening arrhythmias, the use of mexiletine as well as other antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Acute liver injury:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">In postmarketing experience, abnormal liver function tests have been reported, some in the first few weeks of therapy with mexiletine. Most of these have been observed in the setting of congestive heart failure or ischemia and their relationship to mexiletine has not been established.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196174\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Novo-Mexiletine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196218\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiarrhythmic Agent, Class Ib</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196177\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ventricular arrhythmias (life-threatening): </b>Oral: Initial: 200 mg every 8 hours (may load with 400 mg if necessary); adjust dose in 50 or 100 mg increments no more frequently than every 2 to 3 days; usual dose: 200 to 300 mg every 8 hours; maximum dose: 1.2 g/day. <b>Note:</b> Once controlled, patients may be transferred to an every 12-hour dosing schedule; do not exceed 450 mg every 12 hours with this regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Conversion: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Switching from other oral antiarrhythmics (eg, disopyramide, quinidine sulfate):</i> Initiate 200 mg dose of mexiletine 6 to 12 hours after the last dose of the former agent.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Switching from IV lidocaine:</i> Initiate 200 mg dose of mexiletine when lidocaine infusion is stopped.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Switching from oral procainamide:</i> Initiate a 200 mg dose of mexiletine 3 to 6 hours after the last dose of procainamide.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myotonic dystrophy (type 1) (off-label use):</b> Oral: 150 mg 3 times daily (Logigian 2010). <b>Note:</b> It is prudent to obtain a cardiology consult prior to beginning therapy. Additional data is necessary to further define the role and long term safety of mexiletine in the treatment of this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Premature ventricular complex (symptomatic) suppression (off-label use):</b> Oral: 100 or 150 mg 3 times daily; if not controlled, may increase to 200 mg 3 times daily (Saikawa 1992; Tanabe 1991) <b>or</b> 100 or 200 mg 2 to 3 times daily; may progressively increase to a maximum dose of 500 mg 3 times daily (Rutledge 1985)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196178\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20324082\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196179\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. Patients with hepatic impairment or hepatic congestion secondary to heart failure may require dose reduction; half-life is approximately doubled in patients with hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196151\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 150 mg, 200 mg, 250 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196137\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196155\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer around-the-clock rather than 3 times daily to promote less variation in peak and trough serum levels; administer with food or antacid</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196154\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ventricular arrhythmias:</b> Management of life-threatening ventricular arrhythmias</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: </b>The American College of Cardiology/American Heart Association/European Society of Cardiology (ACC/AHA/ESC) states that mexiletine may be considered for those with long QT syndrome who present with torsades de pointes (ACC/AHA/ESC [Zipes 2006])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28744450\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Myotonic dystrophy (type 1); Suppression of symptomatic premature ventricular complexes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196144\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Exacerbation of cardiac arrhythmia (10% to 15%; patients with malignant arrhythmia)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (11% to 25%), ataxia (10% to 20%), nervousness (5% to 10%), unsteady gait</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gastrointestinal distress (41%), nausea (&le;40%), vomiting (&le;40%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Tremor (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Palpitations (4% to 8%), chest pain (3% to 8%), angina pectoris (2%), ventricular premature contractions (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Insomnia (5% to 7%), numbness (fingers or toes: 2% to 4%), depression (2%), paresthesia (2%), confusion, headache</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (&le;5%), diarrhea (&le;5%), xerostomia (3%), abdominal pain (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (5%), arthralgia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision (5% to 7%), nystagmus (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Tinnitus (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Agranulocytosis, alopecia, amnesia (short-term), atrioventricular block, cardiac conduction disturbance, cardiac failure (patients with pre-existing ventricular dysfunction), cardiogenic shock, decreased libido, diaphoresis, diplopia, dysphagia, edema, esophageal ulcer, exfoliative dermatitis, hallucination, hepatic necrosis, hepatitis, hot flash, hypertension, hypotension, impotence, increased liver enzymes, increased serum transaminases, leukopenia, lupus-like syndrome (drug-induced), malaise, myelofibrosis (patients with pre-existing myeloid abnormalities), pancreatitis (rare), peptic ulcer, pharyngitis, positive ANA titer, psychological disorder, psychosis, pulmonary fibrosis, salivary gland disease, seizure, sinoatrial arrest, Stevens-Johnson syndrome, syncope, thrombocytopenia, torsades de pointes, upper gastrointestinal hemorrhage, urinary hesitancy, urinary retention, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196158\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Cardiogenic shock; second- or third-degree AV block (except in patients with a functioning artificial pacemaker)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196141\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood dyscrasias: Rare marked leukopenia, agranulocytosis, and thrombocytopenia have been reported; often occurs in seriously ill patients receiving other medications that can cause these effects. If significant hematologic changes occur, discontinue therapy (blood counts usually return to normal within a month of discontinuation).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug reactions with eosinophilia and systemic symptoms: Drug reactions with eosinophilia and systemic symptoms (DRESS) has been reported. Discontinue if DRESS is suspected. Symptoms of DRESS include eosinophilia, fever, rash, and/or lymphadenopathy in association with other organ involvement, such as hepatitis, nephritis, hematologic abnormalities, myocarditis, or myositis, sometimes resembling an acute viral infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity:<b> [US Boxed Warning]: Abnormal liver function tests have been reported, some in the first few weeks of therapy. Most of these have been observed in the setting of congestive heart failure or ischemia and their relationship to mexiletine has not been established.</b> Marked elevations of AST (&gt;1000 units/L) and rare instances of severe liver injury, including hepatic necrosis, have also been reported. Carefully monitor patients who develop abnormal LFTs or who have signs/symptoms of liver dysfunction. If persistent or worsening elevation of hepatic enzymes occurs, consider discontinuing therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Proarrhythmic effects: Proarrhythmia may occur with the use of mexiletine especially in those with life-threatening arrhythmias (eg, sustained ventricular tachycardia). Aggravation of arrhythmia may also occur; monitor for proarrhythmic effects (Podrid 1987; Podrid 1999; Velebit 1982).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conduction disturbances: Use with caution in patients with intraventricular conduction delays, first-degree heart block and/or preexisting sinus node dysfunction. Use is contraindicated in patients with second- or third-degree AV block (except in patients with a functioning artificial pacemaker).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy (Podrid 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure (HF): Use with caution in patients with severe HF; may precipitate or exacerbate condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; may prolong the elimination half-life of mexiletine and increase the risk of adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure: Use with caution in patients with seizure disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Initiate therapy in the hospital when used to treat life-threatening arrhythmias. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Has not been shown to enhance survival in patients with ventricular arrhythmias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CAST trial:<b> [US Boxed Warning]: In the Cardiac Arrhythmia Suppression Trial (CAST), recent (&gt;6 days but &lt;2 years ago) myocardial infarction patients with asymptomatic, nonlife-threatening ventricular arrhythmias did not benefit and may have been harmed by attempts to suppress the arrhythmia with flecainide or encainide. An increased mortality or nonfatal cardiac arrest rate (7.7%) was seen in the active treatment group compared with patients in the placebo group (3%). The applicability of the CAST results to other populations is unknown. Antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.</b> In a double-blind placebo controlled trial in patients with recent MI, the use of mexiletine to reduce premature ventricular contractions demonstrated a numerically greater number of deaths compared to placebo (IMPACT Research Group, 1984).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Urinary pH: Alterations in urinary pH may change urinary excretion; avoid dietary regimens that may markedly alter urinary pH.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196212\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (major), CYP2D6 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP1A2 (moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196146\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9648&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agomelatine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Agomelatine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alosetron: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Alosetron. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: May increase the serum concentration of Mexiletine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inducers (Moderate): May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Substrates (High risk with Inhibitors): CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyproterone: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: May decrease the serum concentration of Mexiletine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FluvoxaMINE: May increase the serum concentration of Mexiletine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Mexiletine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heroin: May decrease the absorption of Mexiletine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obeticholic Acid: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of sensitive CYP2D6 substrates when possible, particularly those substrates with a narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Substrates (High risk with Inhibitors) may increase the serum concentration of Perhexiline. Perhexiline may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of Mexiletine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: Use any such combination with caution and close monitoring for pirfenidone toxicity. Avoid the use of pirfenidone with moderate CYP1A2 inhibitors whenever CYP2C9, 2C19, 2C6, or 2E1 is also inhibited (either by the CYP1A2 inhibitor or by a third drug).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rasagiline: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Rasagiline. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Mexiletine.<b> Exceptions: </b>Sertraline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of Mexiletine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Mexiletine may decrease the metabolism of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiZANidine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of TiZANidine.  Management: If combined use cannot be avoided, initiate tizanidine in adults at 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vemurafenib: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). Management: Consider alternatives to such combinations whenever possible, particularly if the CYP1A2 substrate has a relatively narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196169\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food may decrease the rate, but not the extent of oral absorption; diets which affect urine pH can increase or decrease excretion of mexiletine. Management: Avoid dietary changes that alter urine pH.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196148\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14206276\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. A few case reports have demonstrated safe use of mexiletine in pregnant women (Gregg 1988; Lownes 1987; Timmis 1980).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13376290\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Mexiletine is excreted in breast milk; concentrations in breast milk are similar to those in the maternal plasma. Breastfeeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15577079\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver function tests, ECG</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196152\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Therapeutic range: 0.5 to 2 mcg/mL; potentially toxic: &gt;2 mcg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196140\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Class IB antiarrhythmic, structurally related to lidocaine, which inhibits inward sodium current, decreases rate of rise of phase 0, increases effective refractory period/action potential duration ratio</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196157\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: 30 to 120 minutes (with loading regimen)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 5 to 7 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 50% to 60% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via CYP2D6 metabolism to inactive metabolites (~90%) and major metabolites p-hydroxymexiletine, hydroxy-methylmexiletine,  and N-hydroxy-mexiletine (minimal antiarrhythmic activity); low first-pass effect </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: 90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~10 to 12 hours; ~ 15 hours in severe renal impairment (CrCl &lt; 10 ml/min); ~ 25 hours in moderate to severe hepatic impairment  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 2 to 3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (10% as unchanged drug); urinary acidification increases excretion, alkalinization decreases excretion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196160\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Mexiletine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (100): $253.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (100): $302.67</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $349.81</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038680\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Lefotil (KR);</li>\n      <li>Meksartym (UA);</li>\n      <li>Meletin (MY, TW);</li>\n      <li>Mexicord (PL);</li>\n      <li>Mexilate (LK);</li>\n      <li>Mexitec (ID);</li>\n      <li>Mexitil (AE, AT, AU, BB, BE, BG, BH, BM, BS, BZ, CH, CY, CZ, DE, DK, EE, EG, FI, FR, GB, GR, GY, HN, HR, HU, IE, IL, IN, IQ, IR, IT, JM, JO, JP, KW, LB, LU, LY, MT, NL, NO, NZ, OM, PT, QA, RU, SA, SE, SK, SR, SY, TR, TT, TW, VN, YE);</li>\n      <li>Mexitilen (AR);</li>\n      <li>Ritalmex (HU);</li>\n      <li>Tumetil (VE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Echt DS, Liebson PR, Mitchell LB, et al, &ldquo;Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo: The Cardiac Arrhythmia Suppression Trial,&rdquo; <i>N Engl J Med</i>, 1991, 324(12):781-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mexiletine-drug-information/abstract-text/1900101/pubmed\" target=\"_blank\" id=\"1900101\">1900101</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flaker GC, Blackshear JL, McBride R, et al, &ldquo;Antiarrhythmic Drug Therapy and Cardiac Mortality in Atrial Fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators,&rdquo; <i>J Am Coll Cardiol</i>, 1992, 20:527-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mexiletine-drug-information/abstract-text/1512329/pubmed\" target=\"_blank\" id=\"1512329\">1512329</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gregg AR, Tomich PG. Mexiletine use in pregnancy. <i>J Perinatol</i>. 1988;8(1):33-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mexiletine-drug-information/abstract-text/3236091/pubmed\" target=\"_blank\" id=\"3236091\">3236091</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Impact Research Group. International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings. <i>J Am Coll Cardiol</i>. 1984;4(6):1148-1163.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mexiletine-drug-information/abstract-text/6209318/pubmed\" target=\"_blank\" id=\"6209318\">6209318</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20439846\"></a>Logigian EL, Martens WB, Moxley RT 4th, et al. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. <i>Neurology</i>. 2010;74(18):1441-1448.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mexiletine-drug-information/abstract-text/20439846/pubmed\" target=\"_blank\" id=\"20439846\">20439846</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lownes HE, Ives TJ. Mexiletine use in pregnancy and lactation. <i>Am J Obstet Gynecol</i>. 1987;157(2):446-447.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mexiletine-drug-information/abstract-text/3618696/pubmed\" target=\"_blank\" id=\"3618696\">3618696</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mexiletine hydrochloride [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Podrid PJ, Lampert S, Graboys TB, Blatt CM, Lown B. Aggravation of arrhythmia by antiarrhythmic drugs--incidence and predictors. <i>Am J Cardiol</i>. 1987;59(11):38E-44E.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mexiletine-drug-information/abstract-text/2437788/pubmed\" target=\"_blank\" id=\"2437788\">2437788</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Podrid PJ. Proarrhythmia, a serious complication of antiarrhythmic drugs. <i>Curr Cardiol Rep</i>. 1999;1(4):289-296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mexiletine-drug-information/abstract-text/10980856/pubmed\" target=\"_blank\" id=\"10980856\">10980856</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"4031292\"></a>Rutledge JC, Harris F, Amsterdam EA. Clinical evaluation of oral mexiletine therapy in the treatment of ventricular arrhythmias. <i>J Am Coll Cardiol</i>. 1985;6(4):780-784.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mexiletine-drug-information/abstract-text/4031292/pubmed\" target=\"_blank\" id=\"4031292\">4031292</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1283888\"></a>Saikawa T, Nakagawa M, Takahashi N, et al. Mexiletine and disopyramide suppress ventricular premature contractions (VPC) irrespective of the relationship between the VPC and the underlying heart rate. <i>Jpn Heart J</i>. 1992;33(5):665-678.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mexiletine-drug-information/abstract-text/1283888/pubmed\" target=\"_blank\" id=\"1283888\">1283888</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1724233\"></a>Tanabe T, Takahaski K, Yoshioka K, Goto Y. Evaluation of disopyramide and mexiletine used alone and in combination for ventricular arrhythmias in patients with and without overt heart disease. <i>Int J Cardiol</i>. 1991;32(3):303-312.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mexiletine-drug-information/abstract-text/1724233/pubmed\" target=\"_blank\" id=\"1724233\">1724233</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Timmis AD, Jackson G, Holt DW. Mexiletine for control of ventricular dysrhythmias in pregnancy. <i>Lancet</i>. 1980;2(8195 pt 1):647-648.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mexiletine-drug-information/abstract-text/6107439/pubmed\" target=\"_blank\" id=\"6107439\">6107439</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Velebit V, Podrid P, Lown B, Cohen BH, Graboys TB. Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. <i>Circulation.</i> 1982;65(5):886-894.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mexiletine-drug-information/abstract-text/6176355/pubmed\" target=\"_blank\" id=\"6176355\">6176355</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). <i>J Am Coll Cardiol</i>. 2006;48(5):247-346.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mexiletine-drug-information/abstract-text/16949478 /pubmed\" target=\"_blank\" id=\"16949478 \">16949478 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9648 Version 130.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709085\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F196174\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F196218\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F196177\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F196178\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F20324082\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F196179\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F196151\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F196137\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F196155\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F196154\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F28744450\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F196144\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F196158\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F196141\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F196212\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F196146\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F196169\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F196148\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14206276\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13376290\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F15577079\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F196152\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F196140\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F196157\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F196160\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038680\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9648|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=mexiletine-patient-drug-information\" class=\"drug drug_patient\">Mexiletine: Patient drug information</a></li><li><a href=\"topic.htm?path=mexiletine-pediatric-drug-information\" class=\"drug drug_pediatric\">Mexiletine: Pediatric drug information</a></li></ul></div></div>","javascript":null}